Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2025 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce that it has received firm commitments from new and existing investors and Directors and Key Management Personnel for a non-underwritten placement of approximately 12.1 million new fully paid ordinary shares at $0.37 per New Share.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, will give an investor briefing at the Alpha ex-100 Conference hosted by Morgan Stanley in Sydney today.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the formation of its Clinical Advisory Board for its world-first diagnostic blood test to identify esophageal cancer, specifically esophageal adenocarcinoma, PromarkerEso.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics has secured new intellectual property protection following the grant of a patent in Australia for the platform technology which precisely measures levels of oxidative stress.
Memphasys Limited (ASX:MEM) (FRA:IG7) is pleased to announce the successful unblinding and data analysis of its pivotal clinical trial for the Felix(TM) System, confirming its best-in-class performance in sperm selection for Assisted Reproductive Technology.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the WA Life Sciences Broker Meets Biotech event, Perth on 20th March 2025.
